Grail received some excellent news from the FDA this week, but there's still a long way to go before the company meets ...

The Vanguard High Dividend Yield ETF maintains a Hold rating amid a dramatically widened yield gap versus Treasuries. Read ...

Now Norway is set to provide a test case for broad restrictions on their use. Up until this week, any bans around the world ...

The U.S. Air Force has fielded the IRIS beyond-line-of-sight communications system on B-52 bombers, improving long-range ...

In this four-part series, data analyst David Stasior argues that AI has made it possible to turn court and disciplinary ...

PE-owned retailers and distributors are spending on AI. Whether they own it or rent it could shape exit values.

AI-aided scanning of speech patterns, vocal stress or facial expressions to read minds lacks scientific backing and will ...

Fitch flags sharp pockets of risk in outsourced services, media production, software and AI infrastructure, and in the ...

ArriVent BioPharma’s Phase 3 lung cancer trial was clouded by stronger-than-expected data for patients receiving chemotherapy, prompting analysts to pivot focus to a late-stage test of the tyrosine ...

The S&P 500 remains near record highs, but weakening market breadth raises concerns as fewer stocks participate and new lows ...

Google has been trailing OpenAI and Anthropic for much of 2026, analysts say Gemini 4 puts it back in the frontier AI ...

A new prompt helps you determine whether the market is overreacting to fears about AI.